We tested the activity of the new fluoroquinolone sparfloxacin ; AT 4140) against 30 strains of Mycobacterium avium complex (MAC) isolated from patients with acquired immune deficiency syndrome.
Some members of the fluoroquinolone class of antimicrobial agents show in vitro activity against Mycobacterium avium complex (MAC) (2, 4, 5) . Ciprofloxacin and WIN 57273 are among the most active compounds in this group of agents (2, 4) , with ciprofloxacin showing inhibitory activity against approximately 30o of MAC strains (11) . Sparfloxacin (CI-978; AT-4140) is a new agent in the fluoroquinolone class of antimicrobial agents (7, 8, 10) . To examine the in vitro activity of this new agent against MAC, we tested sparfloxacin against 30 strains of MAC isolated at San Francisco General Hospital from patients with acquired immune deficiency syndrome (AIDS) and compared this activity with that of ciprofloxacin. In addition, since ciprofloxacin has been shown to act synergistically with ethambutol and rifampin (11) , synergism experiments were performed using sparfloxacin in combination with ethambutol and/or rifampin against 10 of the MAC strains.
Sparfloxacin was provided by Parke-Davis (Ann Arbor, Mich.) and was tested over a range of 0.06 to 4 ,ug/ml. The drug was prepared by adding 10 mg of powder to 0.5 ml of 95% ethanol, then adding 5 ml of sterile distilled water and 2 to 3 drops of 1 N NaOH, and mixing until the powder was dissolved. The volume was brought up to 10 ml with water to achieve a final concentration of 1 mg/ml. Dilutions of the stock solution were prepared in 7HSF broth, a broth medium that is the equivalent of 7H11 agar (12 no turbidity were subcultured (0.1 ml of a 1:10 dilution) to 7H10 agar to determine the MBC(AFB) (13) . The MBC(AFB) is defined as the lowest concentration of drug that kills >99o of the initial inoculum (13) . a Defined as the lowest concentration that kills >99% of the initial inoculum.
survival, as described above. The FIC was calculated as the MIC of drug in combination divided by the MIC of drug alone, and the FBC was calculated as the MBC(AFB) of drug in combination divided by the MBC(AFB) of drug alone (3) . The FIC index is the sum of the FIC for each drug in combination, and the FBC index is the sum of the FBC of each drug in combination (3). Synergism was defined as an FIC or FBC index of c0.5 for combinations involving two drugs (3, 11) , and an FIC or FBC index of 0.75 for combinations of three drugs (11), based on the definition of Berenbaum (1). FIC and FBC indices of sparfloxacin in combination with ethambutol or rifampin or both are shown in Table 2 . The results show that the combination of ethambutol plus sparfloxacin was synergistic against 9 of 10 strains of MAC. The combination of sparfloxacin plus rifampin was synergistic against two strains, additive (IFIC = 1.0) against five strains, and apparently antagonistic (IFIC .2.0) against three strains. In vitro antagonism against MAC by the combination of ciprofloxacin plus rifampin has previously been reported (11) . This antagonism could be overcome by the addition of ethambutol to the two-drug combination (11) . In the present study, the three-drug combination of sparfloxacin plus ethambutol plus rifampin showed synergistic activity (IFIC, s0.75) against all 10 strains of MAC tested. Killing synergism (Y.FBC, 0.75) occurred against 8 of 10 strains of MAC when this three-drug combination was used.
This study demonstrates the following: (i) sparfloxacin is more active in vitro than ciprofloxacin against AIDS-derived 
